Incentives of 5 FU infusions through pump and decrease stay in hospital

Cite this:
[1]
A. A. Samrina Imran, “Incentives of 5 FU infusions through pump and decrease stay in hospital”, ijmhs, vol. 7, no. 2, Apr. 2017.
© 2022 Interactive Protocols
RIGHTS & PERMISSIONS
Article Views
276
Altmetric
1
Citations
-
LEARN ABOUT THESE METRICS
   PDF  

Abstract

Background: In developing countries chemotherapy and their administration cost is the major issue which is addressed by introducing chemotherapy infusion pumps, started for the first time in oncology day care at Aga khan university hospital Karachi Pakistan in the year 2012.Chemotherapy which was studied for this purpose was 5-Florouracil given through 46 or 96 hours infusion pumps implemented in the following regimes:

FOLFOX: Folinic Acid+5-Florouracil+Oxaliplatin

FOLFIRI: Folinic Acid+ 5-Florouracil+Irinotecan

FOLFIRINOX: Folinic Acid +5-Florouracil+Irinotecan+Oxaliplatin

DCF: Docetaxel+Cisplatin+5-Florouracil

The above mentioned Chemotherapy regimens are mostly used in gastrointestinal cancers such as colorectal, gastric and pancreatic cancers.

Methodology: A comparative  study  is done on  cost  difference  and patients  satisfaction, by developing survey forms  and 3  months  data  of  patients  was gathered who were admitted  for  three  to  four  days  in ward to receive chemotherapy and compared  with  those who  were  admitted  in  oncology  day  care for six to eight hours for the same treatment.

Results: Results turned up as remarkable cost reduction, increased convenience, more compliance and hence overall great patient’s satisfaction.

Conclusion: It is concluded that chemotherapy administration in oncology day care for gastrointestinal cancers after introduction of elastomeric portable infusion pumps for 46 or 96 hours of 5-FU not only increased patient’s satisfaction with less financial burden but also enabled patients to perform normal routine activities of life.

KEYWORDS:

 Special Issue

Article Metrics Graph

Chart Graph | Range Graph

Content

Section

Source

License

All paper submissions must carry the following duly signed by all the authors:
“I certify that I have participated sufficiently in the conception and design of this work and the analysis of the data (wherever applicable), as well as the writing of the manuscript, to take public responsibility for it. I believe the manuscript represents valid work. I have reviewed the final version of the manuscript and approve it for publication. Neither has the manuscript nor one with substantially similar content under my authorship been published nor is being considered for publication elsewhere, except as described in an attachment. Furthermore I attest that I shall produce the data upon which the manuscript is based for examination by the editors or their assignees, if requested.”